Source: European Journal of Cancer. Unidade: FM
Subjects: NEOPLASIAS COLORRETAIS (QUIMIOTERAPIA), MUTAÇÃO GENÉTICA, ESTUDOS RETROSPECTIVOS, PROGNÓSTICO, BIOMARCADORES, METÁSTASE NEOPLÁSICA
ABNT
SMITH, John C. et al. KRAS mutations are associated with inferior clinical outcome in patients with metastatic colorectal cancer, but are not predictive for benefit with cediranib. European Journal of Cancer, v. 49, n. 10, p. 2424-2432, 2013Tradução . . Disponível em: https://doi.org/10.1016/j.ejca.2013.02.023. Acesso em: 10 set. 2024.APA
Smith, J. C., Brooks, L., Hoff, P. M., McWalter, G., Dearden, S., Morgan, S. R., et al. (2013). KRAS mutations are associated with inferior clinical outcome in patients with metastatic colorectal cancer, but are not predictive for benefit with cediranib. European Journal of Cancer, 49( 10), 2424-2432. doi:10.1016/j.ejca.2013.02.023NLM
Smith JC, Brooks L, Hoff PM, McWalter G, Dearden S, Morgan SR, Wilson D, Robertson JD, Jürgensmeier JM. KRAS mutations are associated with inferior clinical outcome in patients with metastatic colorectal cancer, but are not predictive for benefit with cediranib [Internet]. European Journal of Cancer. 2013 ; 49( 10): 2424-2432.[citado 2024 set. 10 ] Available from: https://doi.org/10.1016/j.ejca.2013.02.023Vancouver
Smith JC, Brooks L, Hoff PM, McWalter G, Dearden S, Morgan SR, Wilson D, Robertson JD, Jürgensmeier JM. KRAS mutations are associated with inferior clinical outcome in patients with metastatic colorectal cancer, but are not predictive for benefit with cediranib [Internet]. European Journal of Cancer. 2013 ; 49( 10): 2424-2432.[citado 2024 set. 10 ] Available from: https://doi.org/10.1016/j.ejca.2013.02.023